Globocan. Cancer incidence, mortality and

prevalence, World wide version 1.0, IARC

Cancerbase No.5, Lyon, IARC Press. 2020.

Power P.SG, Oza A et al. Improved Survival

with Bevacizumabin Advanced Cervical Cancer.

Gynecol Oncol, 2014;114(3), 410-414.

Moore DH et al. Phase III study of cisplatin with

or without paclitaxel in stage IVB, recurrent,

or persistent squamous cell carcinoma of the

cervix: a Gynecologic Oncology Group study. J

Clin Oncol, 2004;22, 3113-3119.

Lorusso D. PF, Coinu A et al. A systematic

review comparing cisplatin and carboplatin plus

paclitaxel-based chemotherapy for recurrent

or metastatic cervical cancer.Gynecol Oncol,

;133, 115-117.

Monk BJ SM, McMeekin DS et al. Phase

III trial of four cisplatin-containing doublet

combinations in stage IVB, recurrent, or

persistent cervical carcinoma: a Gynecologic

Oncology Group study. J Clin Oncol,

;27(28), 4649-4655.

Kitagawa R, Shibata T et al. Paclitaxel Plus

Carboplatin Versus Paclitaxel Plus Cisplatin

in Metastatic or Recurrent Cervical Cancer:

The Open - Label Randomized Phase III Trial

JCOG0505.J Clin Oncol, 2012;33, 21-29.

Lee K.B, Lee J.M, Park C.Y et al.What is the

difference between squamous cell carcinoma

and adenocarcinoma of the cervix? A matched

case-control study. Int J Gynecol Cancer,

;16(4), 69-73.